Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
March 21, 2024 14:00 ET
|
Oxurion NV
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
March 13, 2024 14:00 ET
|
Oxurion NV
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 13, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
March 07, 2024 13:00 ET
|
Oxurion NV
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 07, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up
March 05, 2024 13:00 ET
|
Oxurion NV
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding ProgramTenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
March 04, 2024 13:00 ET
|
Oxurion NV
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...
Oxurion Announces New Strategic Orientation to De-risk and Diversify
January 22, 2024 16:02 ET
|
Oxurion NV
Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
January 19, 2024 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
January 17, 2024 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
January 12, 2024 02:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM – January 12, 2024 – 8:00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas
December 28, 2023 15:15 ET
|
Oxurion NV
Regulated information – Inside information No bankruptcy filing Significant reduction in Working Capital costsAtlas commits to fund Oxurion’s Working Capital costs (including the Preclinical GA...